MNPR
What one share of Monopar Therapeutics holds
Pharmaceutical Preparations
Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we,” “us,” and “our” and similar terms mean Monopar Therapeutics Inc. and its subsidiaries except where the context otherwise requires) is a clinical-stage biopharmaceutical company developing an innovative treatment for Wilson disease and novel radiopharmaceuticals for oncology.
Monopar Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.18 |
|---|---|
| Cash and investments | $7.86 |
| Book value | $19.50 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $0.00 | −$9.43 | — | −$1.50 | — | $5.18 |
| 2018 | $0.00 | −$1.74 | — | −$1.44 | — | $3.72 |
| 2019 | $0.00 | −$2.27 | — | −$1.62 | — | $5.96 |
| 2020 | — | −$2.88 | — | −$2.13 | — | $6.85 |
| 2021 | — | −$3.65 | — | −$2.93 | — | $7.52 |
| 2022 | — | −$4.13 | — | −$2.84 | — | $3.90 |
| 2023 | — | −$3.04 | — | −$2.84 | — | $1.87 |
| 2024 | $0.00 | −$4.11 | — | −$1.69 | — | $9.02 |
| 2025 | $0.00 | −$1.85 | — | −$1.65 | — | $20.60 |